Related Experiment Videos
Phase II study of teniposide in advanced breast cancer
J Boas1, D Rasmussen, O P Hansen
1Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.
Cancer Chemotherapy and Pharmacology
|January 1, 1990
Abstract:
In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.